OBJECTIVES: To assess the effects of antiretroviral therapy (ART) on bone mineral density (BMD) DESIGN: Randomized comparison of continuous ART (viral suppression group; VS) with intermittent ART (drug conservation group; DC) SETTING:Outpatient clinics in the United States, Australia, and Spain. PARTICIPANTS: Participants in the Strategies for Management of Antiretroviral Therapy (SMART) Body Composition substudy. MAIN OUTCOME MEASURES: Annual hip and spine BMD by dual-energy radiographic absorptiometry (DXA) and spine BMD by quantitative computed tomography (qCT). METHODS: Comparisons were by intention-to-treat analysis, using longitudinal models for change in BMD. Risk factors for BMD loss were evaluated. RESULTS: The 214 participants (median 44 years, 19% female participants, 73% on ART; median T-scores -0.5 total hip, -0.7 spine DXA, -0.9 spine qCT; 98 randomized to VS and 116 to DC) were followed for a mean 2.4 years. With continuous ART, BMD declined per year by 0.8% (hip), 0.4% (spine DXA), and 2.4% (spine qCT). BMD declined significantly less with intermittent ART. Estimated DC minus VS group differences in mean BMD change through follow-up were 1.4% [hip; 95% confidence interval (CI) 0.6-2.3; P = 0.002], 1.3% (spine DXA; 95% CI 0.1-2.4, P = 0.03), and 3.0% (spine qCT; 95% CI 0.8-5.2, P = 0.007). No consistent drug-specific association with BMD decline was found. In the parent study, 10 of 2753 participants in the VS group and two of 2720 in the DC group reported serious fractures (hazard ratio 4.9; 95% CI 1.1-22.5; P = 0.04). CONCLUSION: Continuous ART is associated with decline in BMD and possibly more fractures relative to intermittent, CD4 cell count-guided ART.
RCT Entities:
OBJECTIVES: To assess the effects of antiretroviral therapy (ART) on bone mineral density (BMD) DESIGN: Randomized comparison of continuous ART (viral suppression group; VS) with intermittent ART (drug conservation group; DC) SETTING:Outpatient clinics in the United States, Australia, and Spain. PARTICIPANTS: Participants in the Strategies for Management of Antiretroviral Therapy (SMART) Body Composition substudy. MAIN OUTCOME MEASURES: Annual hip and spine BMD by dual-energy radiographic absorptiometry (DXA) and spine BMD by quantitative computed tomography (qCT). METHODS: Comparisons were by intention-to-treat analysis, using longitudinal models for change in BMD. Risk factors for BMD loss were evaluated. RESULTS: The 214 participants (median 44 years, 19% female participants, 73% on ART; median T-scores -0.5 total hip, -0.7 spine DXA, -0.9 spine qCT; 98 randomized to VS and 116 to DC) were followed for a mean 2.4 years. With continuous ART, BMD declined per year by 0.8% (hip), 0.4% (spine DXA), and 2.4% (spine qCT). BMD declined significantly less with intermittent ART. Estimated DC minus VS group differences in mean BMD change through follow-up were 1.4% [hip; 95% confidence interval (CI) 0.6-2.3; P = 0.002], 1.3% (spine DXA; 95% CI 0.1-2.4, P = 0.03), and 3.0% (spine qCT; 95% CI 0.8-5.2, P = 0.007). No consistent drug-specific association with BMD decline was found. In the parent study, 10 of 2753 participants in the VS group and two of 2720 in the DC group reported serious fractures (hazard ratio 4.9; 95% CI 1.1-22.5; P = 0.04). CONCLUSION: Continuous ART is associated with decline in BMD and possibly more fractures relative to intermittent, CD4 cell count-guided ART.
Authors: A L Moore; A Vashisht; C A Sabin; A Mocroft; S Madge; A N Phillips; J W Studd; M A Johnson Journal: AIDS Date: 2001-09-07 Impact factor: 4.177
Authors: Todd T Brown; Mary D Ruppe; Rory Kassner; Princy Kumar; Theresa Kehoe; Adrian S Dobs; Joseph Timpone Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Grace A McComsey; Michelle A Kendall; Pablo Tebas; Susan Swindells; Evelyn Hogg; Beverly Alston-Smith; Carol Suckow; Geetha Gopalakrishnan; Constance Benson; David A Wohl Journal: AIDS Date: 2007-11-30 Impact factor: 4.177
Authors: Sara E Dolan; Jeannie S Huang; Kathleen M Killilea; Meghan P Sullivan; Negar Aliabadi; Steven Grinspoon Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: J Fernández-Rivera; R García; F Lozano; J Macías; J A García-García; J A Mira; J E Corzo; J Gómez-Mateos; A Rueda; J Sánchez-Burson; J A Pineda Journal: HIV Clin Trials Date: 2003 Sep-Oct
Authors: C Amiel; A Ostertag; L Slama; C Baudoin; T N'Guyen; E Lajeunie; L Neit-Ngeilh; W Rozenbaum; M C De Vernejoul Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741
Authors: Benjamin N Breyer; Stephen K Van den Eeden; Michael A Horberg; Michael L Eisenberg; Donna Y Deng; James F Smith; Alan W Shindel Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: Joseph D Perazzo; Allison R Webel; S M Khurshid Alam; Abdus Sattar; Grace A McComsey Journal: J Assoc Nurses AIDS Care Date: 2018-03-28 Impact factor: 1.354
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Michael P Dube; Richard Haubrich; Jeannie Huang; Sharon Riddler; Pablo Tebas; Andrew R Zolopa; Ann C Collier; Todd T Brown Journal: Clin Infect Dis Date: 2013-08-13 Impact factor: 9.079
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Julie A Womack; Joseph L Goulet; Cynthia Gibert; Cynthia Brandt; Chung Chou Chang; Barbara Gulanski; Liana Fraenkel; Kristin Mattocks; David Rimland; Maria C Rodriguez-Barradas; Janet Tate; Michael T Yin; Amy C Justice Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240